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Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease 
characterized by airflow restriction and decreased lung function. It is the 3rd leading 
cause of death worldwide, accounting for approximately 3 million deaths in 2010. It is 
diagnosed using spirometric measurements, including the forced expiratory volume in 
one second (FEV1) and the forced vital capacity (FVC). These measures reflect the 
severity of airway obstruction and predict population morbidity and mortality. The primary 
environmental cause of COPD is cigarette smoking, but genetics also play a role in 
individual susceptibility and disease progression. Genome-wide association studies 
(GWAS) have identified over 30 loci associated with lung, but together the identified 
variants can only explain a small proportion of the variation in spirometric measures and 
a small proportion of the estimated heritability. We hypothesized: 1) rare functional 
variation also affects lung function; and 2) genetic variation (both common and rare) 
affects longitudinal changes in lung function. This dissertation tests these hypotheses 
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Chapter 1. Introduction and literature review 
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease 
characterized by airflow restriction and decreased lung function. COPD results from both 
small airway disease (obstructive bronchitis) and parenchymal destruction (emphysema) 
and typical symptoms include dyspnea, chronic cough, and chronic sputum production. 
These symptoms tend to worsen over time, as and the pathological changes associated 
with COPD are not fully reversible. Individuals with COPD can vary greatly in symptom 
severity, but disease progression typically leads to a decreased capacity for exercise, an 
increased risk of serious comorbidites, and an overall increased mortality rate1,2. 
COPD burden 
COPD is a highly prevalent disease resulting in a substantial economic burden that is 
increasing3. According to the WHO’s Global Burden of Disease, Injuries, and Risk 
Factors Study, COPD is the 3rd leading cause of death worldwide, accounting for 
approximately 3 million deaths in 20104. It is estimated 4.2% of working adults in the 
United States (or 15 million individuals) have COPD, and this number is projected 
increase as the population ages5. This not only poses a large medical burden, but also 
an economic one. The National Heart, Lung and Blood Institute (NHLBI) estimates that 
along with asthma, COPD costs exceeded $60 billion USD in 2008, of which $53.7 
billion USD were direct costs6. The high prevalence and massive economic burden of 
COPD highlight the need for greater understanding of disease etiology to better predict 
individual risk, prevent future disease and treat diagnosed cases.  
Measurement of COPD 
The airflow restriction characteristic of COPD is most often quantified via spirometry, 
including forced expiratory volume in one second (FEV1), forced vital capacity (FVC), 
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and the ratio of FEV1/FVC. These measurements quantify the volume and speed at 
which an individual can exhale air, providing a useful indication of lung function. To 
obtain spirometric measurements, patients are asked to take a deep breath and exhale 
into a sensor as hard as possible, for as long as possible. From this maneuver, one can 
measure: 1) the volume of air exhaled in one second (FEV1); 2) the total volume of air 
exhaled (FVC); and 3) FEV1 as a percent of the predicted value based on height, age, 
sex, and race (FEV1 percent predicted).  
Individuals without obstructive airway disease can expire all (or nearly all) of their vital 
capacity in one second, resulting in an FEV1/FVC ratio about equal to one. Alternatively, 
an FEV1/FVC ratio below 0.7 defines airflow obstruction and is used to diagnose COPD 
(Figure 1.1). 
Spirometric measurements are easily obtained, inexpensive and provide useful 
benchmarks for COPD progression. Moreover, they reliably predict population mortality. 
In a longitudinal study of 15,759 individuals followed over 11 years, those with the most 
severe lung function impairment (FEV1/FVC < 0.7 and FEV1 % predicted < 50%) were at 
a  5.7 times higher risk of death (95% CI = 4.4 - 7.3) than those with normal lung 
function, highlighting the importance of these measurements as indicators of population 
health7. 
However, spirometry is not without limitations. The measurement procedure is highly 
dependent on patient cooperation and effort, and therefore can vary substantially among 
individuals8. Additionally, spirometry does not fully describe all aspects of disease 
pathogenesis, including changes in airway thickness, emphysema and severity of 
symptoms. Thus, while these measurements can confirm the presence of airflow 
obstruction, they do not provide any specific etiologic diagnosis3,9. 
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Etiology of COPD 
COPD is a multifactorial disease with the primary cause being cigarette smoking10. 
However, only 25% of cigarette smokers ever develop COPD11 and even among those 
that do, the rate of lung function decline varies considerably among smokers with similar 
exposure levels12,13. This suggests additional risk factors, including genetics, may play 
some role in individual susceptibility to COPD development and disease progression. 
Environmental risk factors 
Cigarette smoking 
The primary environmental cause of COPD is cigarette smoking. In a 25-year 
prospective cohort study of 8,045 individuals, current smokers were 6.3 times more likely 
to develop clinically significant COPD than never smokers (95% CI = 4.2-9.5)4. 
Approximately 80% of COPD deaths are caused by smoking, and smokers are 12-13 
times more likely to die from COPD than never smokers14. 
Cigarette smoking leads to airflow obstruction and COPD symptoms through a complex 
physiological process. Repeated exposure to the irritants in cigarette smoke causes 
chronic inflammation of the airways, leading to an influx of inflammatory mediator 
molecules (e.g. neutrophils, B cells, and T-lymphocytes)15. Over time, this chronic 
inflammation causes irreversible structural and physiological changes in the lung 
including airway constriction, excess mucus production and dysfunctional cilia16. These 
changes result in expiratory airflow limitation, especially in the smaller (< 2mm) airways, 
and hallmark COPD symptoms, such a wheezing, coughing and dyspnea17. 
Sex 
There are distinct sex differences in COPD prevalence. Overall, men are more likely to 
have COPD, but over the past 20 years COPD prevalence and mortality have increased 
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more rapidly among women18. Sex differences in COPD are frequently attributed to 
different exposure rates (e.g. smoking) between men and women, but there is increasing 
evidence that biological factors may also play a role. Female participants of the National 
Emphysema Treatment Trial (NETT) had fewer pack-years of smoking history than men 
but had similarly severe COPD19. Additionally, a meta-analysis by Gan et al. found that 
females had a faster annual rate of decline in lung function (measured as FEV1) than 
males of similar smoking levels20. Overall, research suggests women develop more 
severe COPD at younger ages with lower levels of exposure to smoking19–21. Proposed 
explanations for this disparity include: 1) differential susceptibility to the effects of 
tobacco, 2) anatomical differences (e.g. smaller lungs and airways), and 3) differential 
responses to treatments22.  The effect of sex on COPD development and progression is 
likely due to a combination of environmental and biological factors, however the exact 
mechanism resulting in this disease disparity remains unresolved.  
Race  
Differences in lung function between European Americans (EAs) and African Americans 
(AAs) are well documented. Prevalence of any impairment in lung function is higher 
among EAs than AAs23. According to the CDC, the age adjusted mortality rate from 
COPD is 46.0 per 1000 in EA and 27.2 per 1000 in AA individuals24.  
However, mortality from COPD is increasing more rapidly among AAs25, and there is 
evidence that AAs may be more susceptible to the negative effects of tobacco 
smoke26,27. In 2004, Chatalia et al. reported that among 80 EA and 80 AA patients with 
advanced COPD, AAs were younger with less cumulative smoking history despite 
comparable lung function28. More recently, differences in between EA and AAs have 
been studied in the COPDgene study, an observational case-control study of 10,000 
smokers with and without COPD29. Investigators found AAs were much more likely to 
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have severe-early onset COPD than EAs (42% vs. 14%) and had different patterns of 
emphysema distribution over the lung region30. The potential impact of racial differences 
in COPD development has important implications on disease is screening, diagnosis and 
treatment, and more research is needed to understand why racial disparities may exist. 
Age 
Aging is associated with a progressive decline in lung function even among non-smoking 
adults31. It remains unclear if this change results from the normal aging process (i.e. 
age-related changes in pulmonary mechanics, respiratory muscle strength, gas 
exchange and ventilatory control)32 or if age reflects the sum of cumulative exposures 
throughout life leading to lung function decline3. 
Other environmental risk factors 
A number of additional risk factors are associated with an increased risk of COPD 
including occupational dust exposure21,34, air pollutants35, history of respiratory infection 
36, asthma37–39, nutrition40,41, second-hand smoke exposure42, and socio-economic 
status43. The relative contribution of these diverse risk factors to COPD development 
and progression remains unresolved, and many may be especially important 
contributors to disease in non-smokers3. 
Genetic risk factors 
There is substantial evidence that genetic factors can influence COPD susceptibility44–51. 
Early familial aggregation studies found severe, early onset COPD probands were 
significantly more likely to have first-degree relatives with decreased FEV1 than 
controls51. More recently, a large population-based study of 821 cases and 776 smoking 
controls showed individuals with a parental family history of COPD were 1.73 times more 
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likely to have disease than those without a family history49, indicating COPD aggregates 
in families which could reflect either shared genetics or shared environment.  
The estimated heritability, or proportion of variance in lung function attributable to the 
additive effects of genes, is 52%, 54% and 45% for FEV1, FVC and FEV1/FVC 
(respectively). This means a considerable proportion of the variation in these spirometric 
measurements is due to genetic factors50.  
Alpha-1 antitrypsin deficiency 
The best understood genetic risk factor of COPD is a mutation on chromosome 14 in the 
gene coding the serine protease inhibitor alpha-1 antitrypsin. The role of alpha-1 
antitrypsin deficiency in lung disease was first identified in 1963 by Carl-Bertil Laurell 
when he noted the absence of alpha-1 antitrypsin protein in the plasma of many early 
onset emphysema cases52. This absence was eventually traced back to a missense 
mutation in the alpha-1 antitrypsin gene that occurs when a glutamic acid is substituted 
for a lysine at amino acid position 342 leading to a non-functional protease inhibitor52. 
Individuals homozygous for this null mutation display markedly decreased alpha-1 
antitrypsin levels, typically leading to lung tissue degradation and early-onset, severe 
COPD53. Although well-characterized, this mutation is relatively rare in the population, 
and accounts for only 1-2% of all COPD cases, suggesting other genetic factors control 
disease susceptibility54.  
Genome-wide association studies 
A number of investigators have attempted to characterize common genetic variation 
influencing lung function using genome-wide association studies (GWAS). In 2009, Pillai 
et al. identified an association between variants in the CHRNA3/CHRNA5 gene cluster 
on chromosome 15q25 and COPD case-control status in 823 cases and 810 smoking 
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controls of European descent55. Subsequent work has replicated this association and 
implicated a nearby gene in tight linkage disequilibrium, IREB2, as the likely candidate 
gene underlying this association56. Concurrent to the Pillai et al. GWAS, Wilk et al. 
conducted an independent GWAS of lung function in 7,691 Framingham Heart Study 
participants, using FEV1/FVC ratio as a quantitative outcome57. They identified 4 single 
nucleotide polymorphisms (SNPs) near the hedgehog interacting protein (HHIP) gene as 
genome-wide significant (p < 5x10-8). HHIP is a regulatory protein in the hedgehog 
signaling pathway and may influence fetal lung development, although its role in lung 
disease remains unclear57. Finally, Cho et al. identified an association between FAM13A 
loci and case-control status using in 2,940 cases and 1,380 controls from 3 independent 
study populations58 (ECLIPSE59, NETT60, and Norway61). In summary, early GWASs with 
modest sample sizes identified three genes (IREB2, HHIP, and FAM13A) associated 
with COPD and its related qualitative outcomes. 
Large scale meta-analyses  
More recently, investigators have leveraged the large sample sizes afforded by ongoing 
cohort studies to test for association between common markers and lung function 
outcomes. Three large meta-analyses of GWAS data have identified 25 additional loci 
associated with lung function outcomes. In 2010, Hancock et al. identified 4 novel loci 
associated with FEV1/FVC in 20,890 participants of European descent in the Cohorts for 
Heart and Aging Research in Genetic Epidemiology (CHARGE) studies. Associated 
SNPs were located in or near the genes: GPR126, ADAM19, PTCH1 and PID162. 
Concurrently, Repapi et al. identified 5 novel loci in 20,288 individuals who were part of 
the SpiraMeta Consortium studies. Associated markers were located in the following 
genes: TNS1, GSTCD, HTR4, AGER, THSD463. Finally, in the largest meta-analyses of 
lung function to date, Soler-Artigas et al. combined these two large meta-analyses 
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(CHARGE and SpiraMeta) to evaluate 2.5 million SNPs in 48,201 individuals of 
European ancestry. This analysis identified 16 novel genetic loci associated with 
FEV1/FVC including variants in and near the genes: MFAP2, TGFB2, HDAC4, RARB, 
MECOM, SPATA9, ARMC2, NCR3, ZKSCAN3, CCDC38, C10orf11, LRP1, CCDC38, 
MMP15, CFDP1 and KCNE2 64.  Previously identified associations between genetic 
markers and lung function in European derived populations are summarized in Figure 
1.2.  
Lung function decline 
COPD development is likely influenced by both: 1) impaired attainment of maximal lung 
size and function before adulthood; and 2) accelerated lung function decline. Cross-
sectional studies cannot differentiate between these pathways, and it is probable 
different risk factors (both genetic and environmental) separately influence each 
pathway. However, few studies have assessed the genetics of lung function decline, as 
this requires longitudinal data.  
To date, there have been three published GWASs of lung function decline, all in 
populations of European ancestry. A summary of these studies is provided in Table 1.1. 
Overall, 6 genes have been identified as associated with lung function decline, none of 
which overlap the reported associations from studies of cross-sectional lung function65–
67. However, there is little agreement between the 3 published studies regarding which 
genes contribute to this decline phenotype, suggesting additional replication and further 
research is necessary. 
Genetic risk factors in African Americans 
Despite increasing evidence that African Americans may be especially susceptible to the 
negative effects of tobacco smoke26,27, there has been little analysis of the genetic 
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determinants of lung function in this sub-population. GWAS analysis in 3,260 AA 
participants of the COPDgene study identified one locus significantly associated with 
FEV1/FVC (near BC011998 on chromosome 5, p-value=1.31x10-8) and one marginally 
significant locus associated with FEV1 (near MGAT3 on chromosome 22, p-value = 
9.19x10-8)68. Additionally, admixture mapping of this population identified an intronic 
variant in FAM19A2 as being associated with FEV1/FVC69. However, compared to 
European-derived populations, few studies have been conducted in African Americans, 
and little is known about the genes controlling lung function in this sub-population. 
Motivation and specific aims for this study 
Substantial advances have been made in our understanding of the genetic etiology of 
COPD through GWAS and candidate gene studies. However, despite large sample 
sizes, together all known associated markers account for only 3.2% of the estimated 
heritability of FEV1/FVC and 1.5 % of the estimated heritability of FEV170. Moreover, little 
is known about the genetic determinants of these measurements in African Americans. 
Together, this suggests much of the genetic variation controlling reduced pulmonary 
function has yet to be discovered. We seek to address this issue though the following 
specific aims: 
1. To identify functional genetic variants associated with lung function in 
European and African American participants of the COPDgene study using 
exome array data. 
 
2. To identify genetic variants associated with longitudinal changes in lung 
function in European American and African American participants of the 




COPDgene is an observational study conceived in 2008 to investigate the genetic and 
environmental etiology of COPD29. Participants included 10,280 self-identified AAs or 
EAs between the ages of 45 and 80 years with a minimum of 10 pack-years of smoking 
history recruited from 21 study centers across the United States. Study exclusion criteria 
included those with a history of lung disease (other than asthma), previous surgical 
removal of at least one lung lobe, active cancer treatment, suspected lung cancer, metal 
in the chest, exacerbated COPD treated with antibiotics/steroids, known alpha-1 
antitrypsin deficiency, recent eye surgery, and inability to use albuterol, self-identified as 
multiple racial categories, having a first or second degree relative in the study, and 
pregnant women. Subjects completed detailed questionnaires, pre- and post-
bronchodilator spirometry, volumetric computed tomography (CT) of the chest, and 
provided a DNA sample for genotyping.  
Genotyping platforms 
Available genotyping platforms included: 1) The Illumina Omni Express BeadChip 
GWAS array containing approximately 733,000 common single nucleotide polymorphic 
(SNPs) variants; and 2) Illumina HumanExome chip 12v1-1 (or 12v1-2) exome array 
containing approximately 233,000 (mostly) functional genetic variants located in gene 
exons. 
Longitudinal follow-up 
In 2013, eligible COPDgene participants returned for a 5-year follow-up assessment, 
affording investigators the opportunity to assess determinates (both genetic and 
environmental) of decline in lung function.  As of November 2015, longitudinal data from 




Many recent advances have been made in our understanding of COPD risk factors. 
However, important determinates (both genetic and environmental) remain unidentified. 
This dissertation aims to identify functional genetic risk factors associated with reduced 
lung function and longitudinal lung function decline, using exome and genome-wide 
array data. Ultimately, improved understanding of COPD risk factors of can aid in 
tailoring treatment, discovering novel therapeutic interventions and in developing 
effective prevention strategies, and this is especially timely given the large and 
increasing global burden of COPD.   
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Figure 1.1  
Volume to time curve for a normal versus obstructed airflow from spirometry. FEV1 is 
the forced expiratory volume in one second. FVC is the forced vital capacity. A 
FEV1/FVC ratio of less than 0.7 defines COPD (Figure adapted from the Global 














Genes associated with lung function (measured as FEV1 or FEV1/FVC) in European-
derived populations (Figure adapted from Wain et al., 201271). 
 
Definition of abbreviations: 1CHARGE= Cohorts for Heart and Aging Research in 














Table 1.1 Summary of published GWAS studies of lung function decline. 
 
 
Definition of abbreviations: 1EGEA = Epidemiological Study of the Genetics and 
Environment of Asthma , 2SAPALDIA = Swiss Cohort Study on Air Pollution and 
Lung and Heart Disease in Adults , 3ECRHS = European Community Respiratory 
Health Survey, 4LHS = Lung Health Study, 5CHARGE = Cohorts for Heart and Aging 




























































Chapter 2. Exome Array Quality Control 
Introduction 
Genome-wide association studies (GWAS) have successfully identified common 
variation related to many complex phenotypes, but typically associated variants account 
for only a small fraction of the estimated heritability. Rare variants (defined here as 
variants with a minor allele frequency less that 5%) are hypothesized to play an 
important role in complex traits but are poorly characterized by GWAS arrays. 
Sequencing, either with whole exome or genome sequencing, can directly assay these 
rare variants but it is expensive and data interpretation is challenging given the large 
amount of data sequencing produces. Therefore, the Illumina HumanExome genotyping 
array (or “the exome array”) was developed to capture known protein coding variation at 
a relatively low cost.  
The exome array contains over 240,000 markers chosen from approximately 12,000 
sequenced exomes based on the following criteria: 1) non-synonymous variants if 
observed at least three times in two or more studies; 2) stop-altering variants if observed 
at least two times in two or more studies; and 3) splice site variants if observed at least 
two times in two or more studies1. The array also contains 3,241 ancestry informative 
markers, 4,761 GWAS tag markers, 3,369 identity-by-descent markers, and 4,651 
randomly selected synonymous markers to aid in quality control1. Previous research 
comparing the exome array to exome sequencing indicates that the coverage of rare, 
functional variants on the array is around 70%2–5 and is comparable between European-
derived and African-derived populations4.  
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Although the exome array affords an exciting opportunity to assess rare coding variation, 
it also introduces novel data processing challenges. Unlike sequencing, genotyping 
platforms depend on automated clustering algorithms (e.g. Illumina’s GenCall) to detect 
and assign genotype calls. These algorithms, originally designed for common variant 
detection, have difficulty accurately making genotype calls for rare variants because few 
observations exist in the heterozygote and homozygote minor allele clusters6,7. This can 
result in misclassified data (i.e. the incorrect assignment of a genotype to a cluster) or 
missing data (i.e. the inability to assign a genotype to a cluster). Additional sources of 
variability in exome array genotype calling include: 1) the sample size available for 
clustering (larger sample sizes improve genotype calling accuracy5); and 2) the manual 
re-clustering steps required by many exome array protocols, which can be subjective6. 
This chapter will describe the quality control (QC) procedures completed in exome array 
data from the COPDgene study, an observation case-control study of smokers with and 
without COPD8. A total of 9,858 Non-Hispanic White (NHW) and African American (AA) 
participants were genotyped on Illumina’s HumanExome platform in addition to 
completing detailed questionnaires, pre- and post- bronchodilator spirometry, and 
volumetric computed tomography (CT) scans. This rich phenotyping, paired with the 
exome array data genotyping, provide a unique opportunity to extend the allelic and 
functional spectrum of genetic variation underlying COPD and COPD-related 
phenotypes. However, adding to the data processing challenges of the exome array, the 
9,858 COPDgene subjects were genotyped in two batches, introducing the possibility of 
batch effects to contend with during the QC process (2,306 subjects on HumanExome 
array version 1.1 at University of Washington and 7,552 subjects on array version 1.2 at 
the Center for Inherited Disease Research). With this in mind, we undertook data 
24 
 
cleaning with the goal of producing a set of high quality functional variants for use by 
COPDgene investigators.  
This chapter aims to: 1) provide a comprehensive description of the COPDgene exome 
array quality control procedures and; 2) to summarize variants available for analysis with 
regard to frequency and functional annotation.  
Methods 
Sample selection 
All eligible participants of the COPDgene study with available DNA (n=9,858) were 
genotyped on Illumina’s HumanExome Beadchip in two batches. Samples in batch one 
were selected based on extreme phenotypes and included NHW subjects with severe 
COPD and NHW disease-resistant smoking controls (n=2,306). Samples in batch two 
included the remaining NHW subjects (not genotyped in batch one) and all AA subjects 
(n=7,552). Therefore, in NHW subjects, chip membership is phenotypically determined 
(Table 1). 
Exome array genotyping 
Batch one was genotyped using version 1.1 of the HumanExome Beadchip (Illumina) at 
the University of Washington. Batch two was genotyped using version 1.2 of the 
HumanExome Beadchip (Illumina) at the Center for Inherited Disease Research at 
Johns Hopkins University. Each batch contained replicate samples (n= 128 in batch 1, 
n=38 in batch 2) and 121 samples were genotyped on both exome arrays to assess 
batch effects. In addition, batch two contained 166 control samples from 8 HAPMAP 
populations.  
Because of differences between array version 1.1 and 1.2, we were unable to pool the 
two batches for joint genotyping calling. Thus, genotypes were called separately by 
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batch using Illumina’s GenTrain clustering algorithm (version 1.0) in GenomeStudio 
(version 2011.1).  
Exome array QC overview  
An overview of the COPDgene exome array QC is provided in Table 2. Briefly, we 
performed: 1) initial single nucleotide variant (SNV) QC in order to combine the two 
exome array datasets 2) sample QC 3) SNV QC; and lastly 4) separated NHW and AA 
subjects for data analysis. All exome array QC was performed in using PLINK version 
2.09 or R10. 
Initial SNV QC 
Because marker identifiers on different exome array versions are inconsistent, we 
mapped all available SNVs to dbSNP version 141. In this process, we removed indels 
(n=276), markers with probable strand issues (n=135), markers that mapped to the 
wrong variant type (e.g. mapped to indel but was a SNV) (n=2), multi-allelic markers 
(n=2,680), and markers that did not map to dbSNP141 (n=617). Additionally, the Illumina 
exome array contains duplicate markers (n=833 on version 1.1, n=815 on version 1.2). 
For each duplicate marker, we checked concordance, dropped any discordant markers 
(n=107), and dropped the SNV with more missingness for concordant markers 
(n=1,541).Together, this initial SNV QC enabled us to merge the two exome array 
datasets for sample QC. Table 2.1 summarizes the initial SNV QC process.  
Sample QC 
A summary of sample QC is provided in Table 2.2.  
GWAS concordance 
All but 5 samples had been previously genotyped with Illumina’s OmniExpress GWAS 
array and thus we could rely on previously performed QC for many of the sample checks 
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as long as concordance between samples was established. Therefore, we calculated 
genotype concordance between exome array samples and GWAS samples on SNVs 
that overlapped between the two platforms (n= >17,000 SNVs).  This was performed 
separately for the first and second chips, as some samples were known to be GWAS 
discordant on the first chip and were re-genotyped on the second chip for that reason. 
Subjects with greater than 500 discordant sites between the two arrays were removed 
from analysis, excluding a total of 13 subjects.  
Call rate 
A low call rate, or fraction of called SNVs per sample, can indicate poor sample quality. 
We calculated call rate per sample using PLINK. This was performed by chip, as some 
markers were unique to either the first chip (n=3,219) or the second chip (n=406). Using 
a cutoff of 95%, no samples were dropped for low call rate.  
Sex check 
We relied on previously performed GWAS QC to exclude subjects with sex 
discrepancies. This excluded one subject. Additionally, there were 7 subjects with sex 
chromosome abnormalities identified in GWAS analysis that were genotyped on the 
exome chips (3 XO individuals, 3 XXY individuals, and 1 XY individual that self-identified 
as a female). These subjects were used in GWAS analysis and are therefore included in 
the exome chip dataset. 
Heterozygosity 
Given a homogenous sample, the heterozygosity rate, or fraction of non-missing 
genotype calls that are heterozygous, can help identify problematic samples (low 
heterozygosity may indicate inbreeding, while high heterozygosity may sample 
contamination). We calculated the heterozygosity using PLINK, separately in NHW and 
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AA subjects. Using a cutoff of greater or less than 6 standard deviations from the mean, 
8 NHW and 4 AA outliers were identified and excluded from analysis.   
Relatedness 
To identify cryptic relatedness, we estimated kinship coefficients between all pairwise 
samples using the Kinship-based Inference for GWAS (KING) software11 (using the 
option: "-kinship -related -degree 2"). All samples were estimated together (excluding 
known duplicates), using all available SNVs. A total of 152 second degree relationships 
were identified by KING, of which 122 had been previously identified and were removed 
(114 removed during GWAS QC process and 8 removed during GWAS concordance 
checks). Additionally, 23 relationships (representing 7 subjects), were removed for 
suspected contamination. Seven additional relationships identified as possible second 
degree relationships by KING (kinship coefficient 0.88-0.95), but not flagged during the 
GWAS QC process, were retained. 
Population outliers 
To identify population outliers, we ran principal components analysis (PCA) separately in 
NHWs and AAs using unlinked, autosomal polymorphisms (n=14,961 SNPs in NHW and 
19,884 SNPs in AAs). These results (using markers from the exome chip) were nearly 
identical to the CPA results using markers from the GWAS chip, and therefore we 
excluded subjects identified as population outliers in the GWAS analysis (n=52) (Figure 
2.3). 
Replicate and control samples 
Replicate samples were genotyped on the first chip (n=128), the second chip (n=38), 
and across the 2 chips (n=121). For all replicates, we calculated genotype concordance 
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between the samples and dropped the one with more missingness. Additionally, we 
excluded 166 HAPMAP genotyping control samples included on chip # 2. 
Fraction of singleton/doubletons 
An excess or depletion of very rare variants can indicate sample quality issues including 
sample contamination, inbreeding or population outliers. Thus, we looked at the number 
of singletons and doubletons per person (separate in NHW and AAs), but did not 
exclude any subjects based on this metric (Figure 2.4).   
Additional GWAS exclusions 
Seven subjects were excluded from analysis for having confirmed alpha-1 antitrypsin 
deficiency. One subject was flagged as mislabeled during the GWAS QC process, and 
therefore was also excluded from the exome array analysis. 
Single Nucleotide Variant (SNV) QC 
A summary of SNV QC is provided in Table 2.3. 
Call rate 
We assessed SNV call rate using PLINK. Because there are some markers unique to 
only one chip, this was performed separately by chip. Using a 95% call rate cutoff, a total 
of 1,394 SNVs were dropped from the first chip, and a total of 4,874 SNVs were dropped 
from the second chip. 
Frequency differences between chips 
To test genotype quality, we compared the allele frequencies of overlapping markers on 
chip v1.1 to allele frequencies on chip v1.2 in NHW subjects. We used two frequency 
mismatch cutoffs to exclude markers: 1) SNVs with absolute frequency differences 
greater than 0.1; and 2) SNVs that were significantly different on a Fisher's exact test of 
variant frequency between controls on each chip (cutoff  = p-value < 10-4). In total, this 
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excluded 180 SNVs. Additionally, we flagged (but did not exclude) markers with p-values 
between 10-3 and 10-4 on the Fisher’s exact test of frequency differences. 
Hardy-Weinberg equilibrium 
We calculated Hardy-Weinberg equilibrium (HWE) by race in unaffected (FEV1/FVC > 
0.70) subjects using PLINK. Markers with HWE p-values less than 10-8 were excluded 
(n=150 in NHW, n=143 in AAs). Markers with HWE p-values less than 10-4 were flagged 
but not excluded from the final dataset. Manhattan plots of HWE p-values by race are 
provided in Figure 2.5. 
Minor allele concordance 
Using the duplicate samples within each chip (n=166) and between the two chips 
(n=121), we calculated minor allele concordance (MAC) and dropped SNVs with MAC < 
95% (n=1,677).  
Non-autosomal markers 
A total of 5,540 markers on the X, Y, XY, and mitochondrial chromosomes were 
removed from analysis. These SNVs were not included in the QC process and require 
additional QC if used in future analyses. 
Chip-specific markers 
There are markers unique to only chip one (n=3,219) or chip two (n=406). Markers 
genotyped on only 1 of the 2 chips are included in the analyzed dataset, but we created 
a flag for consideration during analysis as these SNVs will have will substantial 
missingness which may be non-random (chip membership is phenotype-dependent in 
NHW subjects). 
Annotation 




A total of 6,581 subjects and 233,263 SNVs passed QC in NHWs, and 3,221 subjects 
and 233,255 SNVs passed QC in AAs. The overall call rate on chip one was 99.8% 
(sample range: 98.1% - 100.0%). The overall call rate on chip two was 98.0% (sample 
range: 95.4% – 98.0%). 
Minor allele frequencies and functional annotation 
The minor allele frequency (MAF) distributions for successfully genotyped SNVs are 
described (by race) in Table 2.4. There were 82,832 monomorphic SNVs in NHWs 
(35.5%) and 86,605 monomorphic SNVs in AAs (37.1%). The majority (> 87%) of 
variants in both NHWs and AAs have a MAF < 5% and many (> 37%) have a MAF < 
0.005%. NHW subjects have more variants with a MAF less than 0.001 (90,946 in NHW 
vs. 55,132 in AAs), likely attributable to the marker contents of the chip (chosen from 
primarily NHW exomes) and to the number of AAs genotypes (about half the number of 
NHWs).  
Greater than 92% of genotyped SNVs in both NHWs and AAs are functional (annotated 
as nonsynonomous, stopgain, stoploss, or splicing). The most common function 
category is nonsynonomous, as it accounts for 90% of all genotyped SNVs. A summary 
of the functional categories of observed SNVs by MAF is provided in Table 2.5.  
Genes with multiple SNVs 
Given that the vast majority of observed variants are rare, traditional approaches testing 
for the association of a single variant and outcome are underpowered. To address this, 
many have suggested different collapsing methods where sets of rare variants in a given 
genomic unit (e.g. gene) are “collapsed” and collectively tested for an association with 
the outcome. This test is more powerful than a single variant test if the collapsed 
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variants are causal. To assess our ability to perform “collapsing” tests by gene, we 
summarized the number of variants in each gene by MAF category (Table 2.6).  
There are 16,142 genes in NHWs and 15,932 genes in AAs with more than one 
observed variant. The median number of rare (MAF < 5%) variants per gene was 5 in 
both NHW and AAs. Three genes had an usually high number (>100) of observed 
variants TTN, MUC16 and OBSCN, but these genes are large and known to contain a 
high number of variants. Together, these analyses indicate that the majority of genes 
observed in the COPDgene exome array data have multiple rare variants, and are 
therefore eligible to be used in “collapsing” tests. 
Coverage of COPD-associated genes 
Previous research has been successful in identifying common variation associated with 
COPD through genome-wide association studies (GWAS)13. While GWAS-associated 
SNPs may identify important genetic regions, they are likely not causal and only tag 
functional mutations. Because the exome array directly queries functional variants, we 
have the opportunity to potentially elucidate causal mutations explaining previously 
identified GWAS signals. Thus, we assessed the number of observed variants by MAF 
category in 26 genes associated with lung function in a recent large meta-analysis of 
48,201 NHW subjects14 (Figure 2.6).  
The number of variants per lung function-associated gene ranged from (0-50). One gene 
(CDC123) was not observed in our data. As expected, the majority of SNVs in lung 




The COPDgene NHW subjects were genotyped at two time points, with different 
versions of the exome array. However, 121 subjects were genotyped on both chips. We 
used these duplicated samples to assess batch effects.  
Figure 2.7 shows variant counts in different frequency categories (e.g. singleton, 
doubleton) in the 121 duplicates samples. If no batch effect were present, we would 
expect counts in each category to be equal. However, we see that there are slightly 
fewer variants called and slightly more monomorphic markers in the first chip than the 
second chip, suggesting there may be some under calling of rare variants in chip one. 
Potential reasons for this include: 1) differences in genotype clustering and calling 
between the 2 arrays; and 2) the larger sample size used for calling chip two.  
We also calculated minor allele concordance (the number of concordant minor alleles 
over the total number of minor alleles) between duplicated samples. Overall the minor 
allele concordance between samples genotyped on both chips was high (> 99%) for all 
frequencies (Table 2.7). Together, this suggests there are subtle but present batch effect 
in the NHW exome array data. 
Discussion 
This chapter describes the quality control procedures completed in the COPDgene 
exome array data. Through multiple subject and variant QC steps, we produced a high 
quality dataset to be tested for associations with lung function and the wide array of 
COPD-related outcomes available in the COPDgene study. We have shown that this 
data consists of mostly rare and potentially protein altering variants, including many 
genes with multiple rare variants and genes previously associated with lung function. 
This data provides researchers with an opportunity to extend the allelic and functional 
33 
 
spectrum of genetic variation underlying COPD, and this chapter serves as a resource 
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Distribution of FEV1/FVC by chip in NHW COPDgene subjects.Chip one samples 
were selected based on extreme phenotypes (severe COPD cases and disease-
resistant smoking controls). Chip two samples included all other COPDgene NHW 











Overview of COPDgene exome array quality control process, including the 
number of subjects and SNVs used for each QC step. We performed: 1) initial 












Summary of initial SNV quality control. We mapped all SNVs to dbSNP 141 to 
create consistent marker names. During this process, we dropped indels, SNVs 
with probable strand issues, markers that were the wrong type (SNV versus 
indel), multi-allelic markers, duplicate markers, and SNVs that were unable to be 














Summary of subject QC in the COPDgene exome array data. A total of 662 
subjects were flagged (including 27 subjects flagged more than once) resulting in 














Comparison of principal components generated from NHW exome array data and 
NHW GWAS data. The x-axis is principal component 2. The y-axis is principal 
















Singleton count versus total minor allele count in A) NHW COPDgene subjects 
(n=6,581) and B) AA COPDgene subjects (n=3,321). Red lines indicate mean counts, 
gray line indicate standard deviations. As expected, NHW subjects have fewer total 
minor alleles than AA subjects (mean NHW = 15,270, mean AAs = 17,000). Outliers in 






















































Manhattan plots of Hardy Weinberg p-values for A) NHW controls (FEV1/FVC > 0.70) 
and B) AA controls (FEV1/FVC > 0.70). The dashed red line denotes the p-value cutoff 
















































































Counts of observed variants by functional type in COPDgene NHW and AAs. SNVs 















Counts of observed variants by gene. The majority of genes have more than one 

















Counts of observed variants in known COPD-associated genes in NHW COPDgene 
exome array. COPD-related genes (n=26) from a large meta-analysis of 48,201 NHW 
subjects14. Dark gray bars indicate counts of variants with MAF > 5%, gray bars indicate 
counts of variants with a MAF between 1% and 5%, and light gray bars counts of 





























Counts of variants by frequency category in 121 duplicated samples. Singletons are 
variants observed once in the dataset, doubletons are variants observed twice in the 
dataset. Overall, there are fewer variants called on the first chip than the second chip 




































Minor allele concordance in 121 subjects genotyped on both exome array #1 and 









































Chapter 3. Exome Array Analysis of Lung Function in the 
COPDgene Study 
Introduction 
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease 
characterized by airflow obstruction and decreased lung function. It is the 3rd leading 
cause of death worldwide, accounting for approximately 3 million deaths in 20101. COPD 
is diagnosed based on spirometric measures of lung volume and flow, specifically the 
ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC). 
The FEV1/FVC ratio reflects the severity of airway obstruction and can predict morbidity 
and mortality in individuals2.  
The primary risk factor for COPD is cigarette smoking, but genetics also play a role in 
individual susceptibility and disease progression3. Over the past several years, 
substantial advances have been made in our understanding of the genetics underlying 
COPD using genome wide association studies (GWAS) and large-scale meta analyses4–
8. However, associated genetic risk factors account for only a small fraction of the 
estimated heritability of lung function8, suggesting much of the genetic variation in 
spirometric measures has yet to be discovered.  
Some of this “missing heritability” may reflect the effects of rare, protein coding variation, 
which cannot be easily tested using the GWAS approach. Nearly every gene contains 
functionally important rare variants9 and recently developed exome array technology, 
which directly types these variants, has been successful in identifying additional loci 
associated with many complex traits10–14.   
To determine if rare coding variation plays a role in lung function, we genotyped 9,858 
participants from the COPDgene study15 with Illumina’s HumanExome Beadchip. We 
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performed both: 1) traditional single variant analysis, which tests for statistical 
association between one variant and an outcome; and 2) gene-based analysis, whereby 
all variants in a gene are “collapsed” and tested together for association with an 
outcome. These gene-based tests are more powerful than single variant tests whenever 
multiple variants in a gene are causal, and can be particularly useful for rare variants 
(minor allele frequency < 5%), where single variant tests offer little statistical power. 
Methods 
Study participants 
We genotyped 9,858 participants of the COPDgene study, an observational study 
conceived in 2008 to investigate the genetic and environmental etiology of COPD. A 
complete study protocol for COPDgene had been described elsewhere15. Briefly, self-
identified Non-Hispanic Whites (NHWs) and African Americans (AAs) between the ages 
of 45 and 80 years with a minimum of 10 pack-years smoking history were enrolled at 21 
study centers across the United States. In addition to completing detailed 
questionnaires, pre- and post- bronchodilator spirometry, and volumetric computed 
tomography (CT) of the chest, participants provided whole blood for DNA extraction and 
genotyping.  
Genotyping and quality control (QC) 
Genotyping was performed with the Illumina HumanExome BeadChip v1.1 at the 
University of Washington or with v1.2 at the Center for Inherited Disease Research 
(CIDR). Genotype calling was performed using GenTrain v1.0 in GenomeStudio v2011.1 
(Illumina). The quality control (QC) process resulted in several samples being dropped 
from the analysis. Sample exclusions included sex discordances (n=1), sample 
duplications (n=309), discordance with previous GWAS typing (n=13), population outliers 
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(n=42), unexpected related subjects (n=111) and samples with high overall 
heterozygosity (n=12). This resulted in a final sample size of 6,581 NHW and 3,221 AA 
subjects.  
A total of 247,870 single nucleotide variants (SNVs) were genotyped on Illumina 
HumanExome BeadChip array v1.1, and a total of 244,770 SNVs were genotyped on 
v1.2. SNVs exclusions were based on call rate < 95% (n=6,268), Hardy-Weinberg p < 
10-8 (n=293), minor allele concordance between duplicate samples < 95% (n=1,677), 
non-autosomal SNVs (n=5,540) and significant frequency differences between the two 
genotyped arrays (n=180). This resulted in 150,299 SNVs in NHWs and 146,654 SNVs 
in AAs available for analysis. A complete description of all quality control procedures is 
provided in chapter 2 of this dissertation.  
Phenotypes 
We analyzed: 1) the ratio of forced expiratory volume in one second to forced vital 
capacity (FEV1/FVC), and 2) the ratio of forced expiratory volume in one second as a 
percent of the predicted value (FEV1 % predicted). After taking a maximal deep breath, 
FEV1 is the volume of air exhaled in one second, while FVC is the total volume of air 
exhaled. The ratio of these two measurements (FEV1/FVC) defines COPD when values 
are < 0.7. Forced expiratory volume in one second as a percent of the predicted value 
(FEV1 percent predicted) is calculated using regression models incorporating race, 
gender, age and height, and is indicator of the severity of airflow obstruction16. 
Spirometry measurements were obtained using a standardized spirometer (EasyOne by 
ndd Medical Technologies) after administering two puffs (180 mcg) of albuterol.  
Statistical analyses 
Single variant analysis 
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We tested SNP-trait associations for FEV1/FVC and FEV1 percent predicted separately 
in NHWs and AAs assuming an additive genetic model using linear regression. All 
analyses were adjusted for age, gender, pack-years smoked, exome array version, and 
principal components (PCs) to control for population stratification within racial groups. 
PCs were calculated using unlinked, autosomal polymorphisms (n= 14,975 in NHW and 
n=19,498 AAs) in Eigensoft17. Single variant tests included only SNVs with a MAF > 
0.5% annotated as being functional (nonsynonomous, stop-gain, stop-loss, splicing or 
ncRNA). Statistical significance for each quantitative phenotype was determined by 
Bonferroni correction (0.05 ÷ 21,394 tests = 2.34 x 10-6 in NHWs and 0.05 ÷ 38,519 tests 
= 1.30 x 10-6 in AAs). 
Gene-based analysis 
We performed gene-based tests using the sequence kernel association test (SKAT)18. 
SKAT has been shown to perform well under various scenarios, including when 
protective, deleterious and null variants are present within a single gene. We tested 
putatively functional, rare (minor allele frequency [MAF] < 5%) variants in genes with ≥ 5 
observed variants. Statistical significance was determined by Bonferroni correction for 
the number of genes tested in each population (α = 5.83 x10-6 for NHW analysis, α = 
5.49 x 10-6 for AA analysis). 
For statistically significant genes, we tested the relative contribution of each variant by 
removing one SNV at a time, and re-calculating the evidence for association across the 
gene using the SKAT statistic. All analyses were adjusted for age, gender, pack-years 




Variant annotation and in-silico functional prediction 
SNVs were annotated using ANNOVAR19 with the RefSeq20 reference genome. In an 
effort to assess the potential functional consequences of variants identified as 
significant, we used the combined annotation dependent depletion (CADD) algorithm 21 
to predict deleterious effect on the gene product and genomic evolutionary rate profiling 
(GERP) scores 22 to indicate the degree of evolutionary conservation of variants.  
Results 
Study participants  
Clinical characteristics of the NHW (n=6,562) and AA (n=3,182) subjects with available 
spirometry data are provided in Table 1 and Figures S3.1-S3.2. On average, AA 
subjects were younger with fewer pack-years exposure and had higher mean FEV1/FVC 
and FEV1 percent predicted. 
Genotypes 
A total of 150,299 SNVs in NHWs and 146,654 SNVs in AAs passed QC and were not 
monomorphic. Greater than 87% of these were rare (MAF < 5%) and greater than 92% 
were putatively functional (annotated as nonsynonomous, stop-gain, stop-loss, ncRNA 
or splicing). The most common functional category was nonsynonomous, representing 
over 90% of all genotyped SNVs.  
Single variant analysis 
We identified four significant single variant associations with spirometry, all of which 
were nonsynonymous mutations (Table 3.2 and Figure 3.1).  Three of these four 
associations had been previously identified in GWAS as genetic risk loci for lung 
function: rs16969968 in CHRNA5 (Asp398Asn, MAF = 36.6%) and rs2070600 in AGER 
(Gly38Ser, MAF = 4.2%). The identified nonsynonomous variant in CHRNA5 had a 
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phred-scaled CADD score of 10.5, indicating it was in the top 10% of deleterious 
predictions21, and a GERP score of 3.88, indicating a high degree of evolutionary 
constraint (a cutoff of 2.0 is commonly used to indicate “constraint” 22). Similarly, in-silico 
functional predictions using CADD and GERP suggest the identified nonsynonomous 
variant in AGER is likely deleterious (CADD score = 18.0, GERP score of 5.82). 
We identified one novel association between a nonsynonomous SNV and FEV1 percent 
predicted in AA COPDgene subjects (rs34664882, p = 2.42 x10-7, MAF= 1.7%). The 
associated SNV is in the gene encoding the ankyrin 1 (ANK1) protein and the minor 
allele (A) is associated with significantly lower FEV1 percent predicted (β = -11.59, 
Figure 3.2). This mutation causes the substitution of a valine for alanine in amino acid 
position 1503, however CADD and GERP did not predict this change to be deleterious 
(CADD score = 2.1, GERP score = -2.53). This variant (rs34664882) was observed in 
NHW subjects at a comparable frequency (MAF = 2.9%), but no association between 
genotype and FEV1 percent predicted was observed in this sub-population (p=0.93). 
Manhattan and QQ plots for all single variant association tests are shown in Figures 
S3.3-S3.5. 
Gene-based analysis 
We identified three significant gene associations with FEV1/FVC or FEV1 percent 
predicted using SKAT (Table 3.3 and Figure S3.6). Associated genes include: AGER on 
chromosome 6 (associated with FEV1/FVC in NHWs, p = 2.01x10-9); ProSAPiP1 on 
chromosome 20 (associated with FEV1 percent predicted in NHWs, p = 2.63x10-6); and 
ANK1 on chromosome 8 (associated with FEV1 percent predicted in AAs, p = 5.27x10-6). 
All gene-based associations were population-specific, and we observed no evidence of 
signal overlap between NHWs and AAs (SKAT p-value for AGER in AAs = 0.52, SKAT 
p-value for ProSAPiP1 in AAs = 0.19, SKAT p-value for ANK1 in NHWs = 0.93). 
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To quantify the relative contribution of each SNV to the gene-based signals, we removed 
one SNV at a time and re-calculated the evidence for association across the gene using 
SKAT (Figure 3.3). In each of the three associated genes, this identified a single, rare 
SNV that accounted for the gene-based signal (i.e. every time that variant was included 
in the re-calculated SKAT, gene-based results were significant, but when it was 
excluded, SKAT results were not significant). The identified SNV in AGER (rs2070600) 
and ANK1 (rs34664882) was the same SNV previously identified in the single variant 
analysis. The identified SNV in ProSAPiP1, rs140282982, was observed in 10 subjects 
(MAF = 0.00076), and a single copy of the minor allele (C) reduced FEV1 percent 
predicted by an average of -31.7 (Figure S3.7). 
Discussion 
We performed single variant and gene-based exome array analysis in NHW and AA 
participants from the COPDgene study to identify functional variation associated with 
quantitative spirometric phenotypes. We replicated previously known GWAS 
associations (rs2070600 in AGER and rs16969968 in CHRNA5), and we identified two 
novel associations in the ANK1 and ProSAPiP1 genes. Association signals in these 
genes were largely driven by a single rare, nonsynonomous variant with a large effect 
(rs34664882 in ANK1 and rs140282982 in ProSAPiP1).  
ANK1 is part of the ankyrin family of proteins that act to attach integral membrane 
proteins to the spectin-actin based cytoskeleton. It plays a key role in cell motility, cell 
activation, cell proliferation, and the maintenance of specific cellular membrane 
domains20. ANK1 is highly expressed in the brain and muscle, and moderately 
expressed in the lung23. Mutations in ANK1 are responsible for hereditary 
spherocytosis24, and this gene (and others in the ankyrin family of proteins) have been 
associated with lung function in previous research: In 2012, Imboden et al. identified a 
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variant in ANK1 (rs7006290) as associated with FEV1 decline in asthmatics (p=5.19 x10-
6) 25. Additionally, Hansel et al. identified an association in the ANK3 gene with FEV1 
decline in 4,048 Lung Health Study participants 26. 
ProSAPiP1, or the proline-rich synapse-associated protein-interacting protein 1 (also 
known as LZTS3), is thought to play a role in regulating cellular growth, although its 
biological function remains largely unknown27. This gene is primarily expressed in the 
brain and kidney, but shows moderate expression in multiple other tissues including the 
lung23. There are no known associations between this gene and clinically defined COPD 
or COPD-related phenotypes, and its role in lung disease remains unclear.  
Our results indicate low frequency, coding variants may account for some known GWAS 
signals, and association signals in newly identified genes may explain a small proportion 
of the population variation in lung function. However, overall we found no widespread 
impact of low-frequency coding variation in lung function. One limitation of our study is 
that the exome array does not cover all functional variants. Specifically, very rare 
variants (such as uncharacterized private mutations) and regulatory variation outside of 
the exome are not genotyped on this platform, and whole genome sequencing may be 
needed for a comprehensive assessment of al variation. We have identified interesting 
results warranting further research to understand the mechanism underlying their role in 
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Single variant associations with spirometry. Putatively functional SNVs with MAF > 0.5% 
were tested for association with FEV1/FVC and FEV1 percent predicted in 6,051 NHW 



















Boxplot of spirometry by A) rs2070600 genotype in the AGER gene; B) rs16969968 
genotype in the CHRNA5 gene; C) rs16969968 genotype in the CHRNA5 gene; and D) 















Regional association results (- log10 p-value) for SNVs in the ANK1 gene for FEV1 
percent predicted in AA COPDgene subjects. Linkage disequilibrium (r2) values from 


















Genes significantly associated with spirometry. Gene-based analyses were conducted 
using SKAT. Only rare (MAF < 5%), nonsynonymous, stop-gain, stop-loss, splicing, and 
non-coding RNA variants in genes with ≥ 5 variants were considered. Genes presented 
in the table are significant after Bonferroni correction for the number of genes tested (α = 



























Assessment of the relative contribution of each SNV to the gene-based SKAT test for A) 
SNVs in AGER; b) SNVs in ANK1; and C) SNVs in ProSAPiP1. We re-calculated SKAT 
p-values removing one SNV at a time, adjusting for age, gender, pack-years smoked, 





Supplementary Figure 3.1 






















Supplementary Figure 3.2 

























Supplementary Figure 3.3 
Manhattan plot of –log10 p-values from a linear regression of outcome on SNV (coded 
additively) controlling for age, gender, pack-years smoked, and 5 principal 
components in NHW subjects (n=6,501). Panel A contains results from the FEV1/FVC 
analysis. Panel B contains results from the FEV1 percent predicted analysis. Only 
functional variants with a MAF > .5% were considered. The red dotted line indicates 
significance level, as determined by Bonferroni correction for the number of SNVs 














Supplementary Figure 3.4 
Manhattan plot of –log10 p-values from a linear regression of outcome on SNV (coded 
additively) controlling for age, gender, pack-years smoked, and 5 principal components 
in AA subjects (n=3,221). Panel A contains results from the FEV1/FVC analysis. Panel B 
contains results from the FEV1 percent predicted analysis. Only functional variants with a 
MAF > .5% were considered. The red dotted line indicates significance level, as 
determined by Bonferroni  correction for the number of SNVs tested (n=38,519). 
















Supplementary Figure 3.5 
Quantile-quantile (QQ) plots for single variant analyses in PLINK by minor allele 



















Supplementary Figure 3.6 
Boxplot of spirometry by rs140282982 genotype in the ProSAPiP1 gene. A copy of the 
minor allele at this SNV reduces FEV1 percent predicted by -31.7 in NHWs (calculated 
by linear regression of outcome on genotype, coded additively, controlling for age, 

























Supplementary Figure 3.7  


















Chapter 4. Genetic determinants of decline in lung function in 














Chapter 4. Genetic determinants of decline in lung function in 
the COPDgene study 
Introduction 
Spirometric measurements, including the forced expiratory volume in one second (FEV1) 
and the forced vital capacity (FVC), reliably reflect the physiological state of the airways, 
and are used to diagnose chronic obstructive pulmonary disease (COPD)1,2. These 
measures are heritable3,4 and a multitude of previous research has assessed genetic 
risk factors for cross-sectional lung function5–9, including a large scale meta-analysis of 
48,201 individuals that identified a total of 26 genetic loci associated with this outcome9. 
However, reduced lung function is likely influenced by both: 1) a failure to attain maximal 
lung size and function before adulthood; and 2) accelerated lung function decline after 
maturity. Cross-sectional studies cannot differentiate between these two pathways, and 
it is probable different risk factors (both genetic and environmental) separately influence 
each one. However, few studies have assessed risk factors for lung function decline, as 
this requires longitudinal data. 
Fletcher and Peto first established cigarette smoking as a key risk factor for accelerated 
lung function decline10, but genetic variation is also hypothesized to play an important 
role. Heritability estimates of longitudinal change in lung function using family and twin 
data range from 10% to 39%4,7,11. To date, there have been three published genome-
wide association studies (GWASs) of lung function decline, all in populations of 
European ancestry12–14. Overall, 6 genes have been identified as associated with lung 
function decline (DLEU7, TMEM26, FOXA1, ANK3, IL16/STARD5/TMC3, and ME3), 
none of which overlap with the reported associations from studies of cross-sectional lung 
function. However, there is little agreement between these 3 published studies regarding 
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which genes contribute to this decline phenotype, suggesting additional replication and 
further research is necessary. 
To assess the role of genetic risk factors in longitudinal changes in lung function, we 
used genotyping array data from a large multicenter study of current and former smokers 
to determine genetic predictors of change in FEV1 and change in the FEV1/FVC ratio. 
Methods 
Study Participants 
Subjects who have completed the 5-year follow-up phase of the COPDgene study were 
included in this preliminary analysis (n=2,000). A complete study protocol for COPDgene 
has been described elsewhere15 but briefly, Non-Hispanic Whites (NHWs) and African 
Americans (AAs) between the ages of 45 and 80 years with a minimum of 10 pack-years 
smoking history were enrolled at 21 study centers across the United States. In addition 
to completing detailed questionnaires, pre- and post- bronchodilator spirometry, and 
volumetric computed tomography (CT) of the chest, participants provided whole blood 
for DNA extraction and genotyping.  
Genotyping and Quality Control (QC) 
Samples were genotyped using two array platforms: 1) Illumina’s OmniExpress GWAS 
array, which contains ~730,000 common single nucleotide polymorphisms (SNPs); and 
2) Illumina’s HumanExome Beadchip (v1.1 or v1.2), which contains ~250,000 functional, 
primarily low frequency variants in recognized exons of the human genome. Sample and 
variant quality control (QC) were performed separately for both the genome-wide and 
exome arrays. A summary of the quality control procedures for the GWAS and exome 




and a complete description of the QC for the exome array is provided in Chapter 2 of this 
dissertation.  
After quality control, genotyping data from the genome-wide marker panel and exome 
arrays were combined (excluding exome array variants also on the genome-wide array), 
and only variants with a minor allele frequency (MAF) > 0.5% were considered for 
analysis. This resulted in a total of 1,394 subjects and 654,976 variants available for 
analysis in the NHW group and 606 subjects and 727,583 variants available for analysis 
in the AA group. 
Principal component analysis 
We performed principal component analysis (PCA) separately in NHW and AA subjects 
using unlinked, polymorphic (MAF > 5%) SNPs that were in Hardy Weinberg equilibrium 
and not in regions known to have long range linkage disequilibrium (LD)16. These 
inferred principal components summarize genetic ancestry and were applied as 
covariates in subsequent statistical analyses to control for population stratification within 
racial group. 
Phenotype and covariate assessment 
We analyzed: 1) the change in FEV1 percent predicted (calculated as FEV1 percent 
predicted at visit 2 minus FEV1 percent predicted at visit 1); and 2) the change in 
FEV1/FVC ratio (calculated as FEV1/FVC at visit 2 minus FEV1/FVC at visit 1). At both 
baseline and the 5 year follow-up, spirometry measurements were obtained using a 
standardized spirometer (EasyOne by ndd Medical Technologies) after administering 
two puffs (180 mcg) of albuterol. FEV1 percent predicted was calculated using race and 
gender-specific regression models based on age, age2, and height2. We used 
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demographic data (including age, gender and smoking habits) from the baseline visit for 
our analysis.   
Statistical Analysis 
Genome-wide association studies 
We performed linear regressions of 5-year change in spirometry on SNP genotype 
coded additively using PLINK17 separately in NHWs and AAs. All association models 
included baseline age, gender, pack-years smoked, baseline spirometry, height, and the 
first 5 (NHWs) or 6 (AAs) principal components to control for population stratification. 
SNP-trait analyses using genotype data from the exome array were also adjusted for 
chip version (v1.1 or v1.2). We declared a variant-trait association to be genome-wide 
significant if the p-value was less than 5 x10-8, and a variant-trait association nominally 
significant of the p-value was less than <1x10-5. 
Candidate lung function decline genes 
We examined genes previously reported in the literature to be associated with 
longitudinal changes in lung function to determine if SNPs in or near these genes were 
associated with change in FEV1 percent predicted or FEV1/FVC in the COPDgene 
cohort. In total, we tested 13 regions, including nine genes/gene clusters with a p-value 
< 1 x10-5 in the Tang et al. paper (ST3GAL3, NFIA, ESRRG/GPATCH2, BAZ2B, 
TMCO3, IL16/STARD5/TMC3, SV2B, MYH11, CACNG4)14, one gene from the Imboden 
et al. paper (DLEU7)13, and three genes from the Hansel et al. paper (TMEM26, FOXA1, 
ANK3)12. Because not all of the sentinel variants in previous studies were available in 
our data, we annotated all SNPs using ANNOVAR18 and the RefSeq19 reference and 
those annotated to one of the 13 gene regions were assessed for association. This 





Clinical characteristics of subjects with follow-up data are presented in Table 2. This 
represents 20.3 % of the total NHW cohort and 18.4 % of the total AA cohort expected to 
complete 5-year follow-up as part of COPDgene. At visit two, 270 subjects (13.5%) had 
changed smoking status, with 219 subjects (11.0 %) changing from current to former 
smokers and 51 subjects (2.6%) changing from former to current smokers.  
GWAS of change in FEV1 percent predicted 
The mean 5-year change in FEV1 percent predicted among NHWs was -1.77 ± 9.63, and 
the mean 5-year change in FEV1 percent predicted among AAs was -2.97 ± 12.03 
(Supplementary Figure 1). There was considerable variability in change in FEV1 percent 
predicted (range in NHW: -46.7 to 36.2, range in AA: -39.1 to 48.6) with 820 subjects 
(41.2 %) increasing FEV1 percent predicted between visit 1 and visit 2. 
Our genome-wide association analyses of change in FEV1 percent predicted yielded no 
statistically significant associations (Figure 1). Quantile-quantile (QQ) plots presented in 
Figure S5 show that there was no evidence of type 1 error inflation (genomic inflation 
factor NHW analysis = 0.994, genomic inflation factor AA analysis = 0.997). There were 
6 SNPs in the NHW analysis and 8 SNPs in the AA analysis that were nominally 
associated (p < 1x10-5) with change in FEV1 percent predicted (Supplementary Table 1). 
None of the associated variants overlapped between the NHW and AA analyses.  
The most statistically significant SNP among NHWs was rs2867387 (β = 2.28, p = 2.7 x 
10-6) located just downstream of the FGA gene. Interestingly, another variant in the 3’ 
UTR of this gene, rs2070022, was also nominally associated with change in FEV1 
percent predicted (β = 2.19, p = 6.8 x 10-6). The most statistically significant association 
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in the AA analysis was an exonic variant in the NUP153 gene (rs16879902, β = -10.9, p 
= 9.06 x 10-7). This variant has a low minor allele frequency (MAF = 0.03) and results in 
a missense substitution of an aspartic acid to an asparagine at amino acid position 90.  
GWAS of change in FEV1/FVC ratio 
Mean 5-year change in FEV1/FVC ratio among NHWs was -0.014 ± 0.06, and mean 5-
year change among FEV1/FVC ratio in AAs was -0.021 ± 0.07 (Supplementary Figure 2). 
Change in FEV1/FVC ranged from -0.34 to 0.29 in NHWs and from -0.29 to 0.31 in AAs 
with 684 subjects (37.0 %) increasing their FEV1/FVC ratio between visit 1 and visit 2. 
Our genome-wide association analysis of change in FEV1/FVC yielded no statistically 
significant associations (Figure 2). QQ plots presented in Figure S5 show there was no 
evidence of type 1 error inflation (genomic inflation factor NHW analysis = 1.010, 
genomic inflation factor AA analysis = 0.999). A total of 11 SNPs in NHWs and 6 SNPs 
in AAs were nominally associated with change in FEV1/FVC ratio (p < 1x10-5) 
(Supplementary Table 2). Nominally significant associations did not overlap the FEV1 
percent predicted analysis nor did they overlap between the NHW and AA analyses.  
The most statistically significant associations in the NHW analysis were two SNPs in 
high LD (r2=0.9) located in the intergenic region between the LOC10050720 and 
HNRNPKP3 genes. (rs12574104, β = -0.027, p = 6.25 x 10-7 and rs16937161, β = -
0.027, p = 9.54 x 10-7). The most statistically significant association in the AA analysis 
was a variant, rs1998292, in the RASSF2 gene (β = -0.028, p = 2.24 x 10-6). This variant 
is located in the intronic regions of the RASSF2 gene and has a minor allele frequency 
of 0.13 in AAs. 
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Candidate lung function decline genes 
We sought corroborative evidence of association for genes previously associated with 
lung function decline (n=13). The most statistically significant SNP association from each 
of the 13 genes is presented in Table 4 (for change in FEV1 % predicted) and Table 5 
(for change in FEV1/FVC). Considering p < 0.001 as suggestive evidence, none of these 
SNPs were associated with change in FEV1/FVC, and three SNPs were associated with 
change in FEV1 percent predicted. Interestingly, SNPs within the NFIA gene were 
associated with change in FEV1 percent predicted in both NHW and AA groups 
(SNP=rs17377218, p=0.0006 in NHWs and SNP= rs1712138, p=0.0009 in AAs). 
Additionally, a SNP within the BAZ2B gene was also associated with change in FEV1 
percent predicted in NHWs (p=0.0002). This variant is located just downstream of the 
previously reported variant associated with change in lung function (genomic position = 
160223047, genomic position of previously associated = 160250021). These two SNPs 
are in moderate linkage disequilibrium (r2 =0.8) in the HAPMAP CEU population20. 
Discussion 
Although genetic risk factors for cross-sectional lung function have been well-studied in 
large scale GWASs5,9,21, comparatively less information is known about longitudinal 
changes in spirometry. We sought to assess the role of genetic risk factors in 
longitudinal changes in FEV1 percent predicted and FEV1/FVC using GWAS and exome 
array data from the COPDgene study, a large multicenter study of current and former 
smokers.  
In our genome-wide analyses, no variants reached statistical significance, suggesting no 
single variant can explain a large portion of the phenotypic variance in lung function 
decline. The top SNP in the change in FEV1 percent predicted analysis, rs17688693, is 
located in the nucleoporin 153 gene (NUP153) on chromosome 6p22. Nucleoporins are 
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responsible for regulating the movement of macromolecules between the nucleus and 
cytoplasm, but they have no known role in lung disease22. The two top associations in 
the change in FEV1/FVC analysis, rs12574104 and rs16937161, were located in the 
intergenic region between two pseudo-genes (LOC100507205 and HNRNPKP3). The 
function of these pseudo-genes remains unknown22. 
Additionally, we sought corroborative evidence of association for genes previously 
associated with lung function decline in three population-based GWASs12–14. One gene, 
nuclear factor 1A (NFIA), showed suggestive evidence of association with change in 
FEV1 percent predicted in both the NHW and AA groups (p=0.0006 in NHWs and 
p=0.0009 in AAs). Genes in the nuclear factor 1 family are highly conserved and function 
as cellular transcription factors. These genes are known to be essential for lung 
maturation23 and variants in this gene have been previously implicated in the asthma 
plus allergic rhinitis phenotype24. Our results support the involvement of this gene in 
change in lung function among adults.  
There are a few limitations to our study. With 1,394 NHW subjects and 606 African 
American subjects, we have limited power to detect associations, especially those with 
modest effect sizes. Additionally, we modeled change in lung function by subtracting 
measures at visit 1 from measures at visit 2 (the “delta method”). Although easy to 
interpret, this may not fully capture differences in disease trajectory in this population. 
Specifically, there is evidence those with moderate disease at baseline have a more 
rapid decline than those with more advanced disease25–27(Supplementary Figure 4.4 and 
Supplementary Figure 4.4). Future analyses may benefit from stratification by baseline 
disease severity. Lastly, changes in lung function are likely to be affected by 
environmental exposures, especially cigarette smoking. Our analyses controlled for 
cumulative pack-years smoked, but did not explicitly model changes in smoking status 
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between visit 1 and visit 2.  Additional work is needed to understand how environmental 
factors and gene by environment interactions affect the rate of lung function decline. 
In summary, we performed genome-wide association studies of change in FEV1 percent 
predicted and FEV1/FVC in a large cohort of smokers. This study should be viewed as 
preliminary analysis, as a sizable portion of COPDgene study participants have yet to 
complete their 5-year follow-up visit. Additional analyses with this larger sample size are 
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Summary of the GWAS and exome array quality control procedures. Genotyping 
data from the GWAS and exome arrays were combined for analysis, resulting in a 
total of 1,394 subjects and 654,976 variants available for analysis in the NHWs 
and 606 subjects and 727,583 variants available for analysis in the AAs. A 
complete description of the GWAS array QC is provided at: 
http://www.copdgene.org/sites/default/files/GWAS_QC_Methodology_20121115.p
df, and a complete description of the exome array QC is provided in Chapter 2 of 
this dissertation.  
Definition of abbreviations: HWE= Hardy Weinberg Equilibrium; MAF= minor allele 
frequency; NHW = Non-Hispanic White; AA = African American; GWAS= 






Clinical characteristics of COPDgene subjects with follow up data. Change in 
FEV1 percent predicted was calculated as FEV1 percent predicted at visit 1 – 
FEV1 percent predicted at visit 2. Change in FEV1/FVC ratio was calculated as 














Manhattan plot of –log10 p-values from a linear regression of change in FEV1 
percent predicted on SNP (coded additively) controlling for age, gender, pack-
years smoked, height, baseline spirometry and principal components. Panel A 
contains results from the NHW analysis. Panel B contains results from the AA 
analysis. Only variants with a MAF > .5% were considered. The red dotted line 
indicates genome-wide significance level (p< 5 x10-8) and the blue line indicates 



















Manhattan plot of –log10  p-values from a linear regression of change in 
FEV1/FVC on SNP (coded additively) controlling for age, gender, pack-years 
smoked, height, baseline spirometry and principal components. Panel A 
contains results from the NHW analysis. Panel B contains results from the AA 
analysis. Only variants with a MAF > .5% were considered. The red dotted line 
indicates genome-wide significance level (p< 5 x10-8) and the blue line indicates 




















Assessment of previously associated lung function decline genes (n=13) with 
change in FEV1 percent predicted in COPDgene. All SNPs annotated to the 
13 regions were tested for association. The most significant SNP for each 
region is presented. P-values less than 0.001 are highlighted. 
 
Definition of abbreviations: SNP = single nucleotide polymorphism; P= P-

















Assessment of previously associated lung function decline genes (n=13) with 
change in FEV1/FVC in COPDgene. All SNPs annotated to the 13 regions were 
tested for association (n=2,023 variants in NHWs, n=2,193 variants in AAs). The 
most significant SNP for each region is presented. P-values less than 0.001 are 
highlighted. 
Definition of abbreviations: N=number;  SNP = single nucleotide polymorphism; 














Supplementary Figure 4.1 
Histograms of change in FEV1 percent predicted in A) COPDgene NHW subjects 
completing follow-up (n=1,394) and B) COPDgene AA subjects completing follow-
up (n=606). The red dashed line indicates mean change in FEV1 percent 






























Supplementary Figure 4.2 
Histograms of change in FEV1/FVC in A) COPDgene NHW subjects completing 
follow-up (n=1,394) and B) COPDgene AA subjects completing follow-up 
(n=606). The red dashed line indicates mean change in FEV1 percent predicted 































Supplementary Figure 4.3 
Quantile-quantile (QQ) plots for single variant analyses of decline phenotypes 












Supplementary Table 4.1 
Associations of the most statistically significant SNPs (P < 1x10-5) with change in 
FEV1 percent predicted in COPDgene NHW (n=1,394) and AA subjects (n=606). 
Reported results are from a linear regression of change in FEV1 percent predicted 
on SNP (coded additively) controlling for age, gender, pack-years smoked, height, 
baseline spirometry, and principal components. 
Definition of abbreviations: CHR = chromosome; SNP = single nucleotide 













Supplementary Table 4.2 
Supplementary Table 2. Associations of the most statistically significant SNPs (P 
< 1 x 10-5) with change in FEV1/FVC in COPDgene NHW (n=1,394) and AA 
subjects (n=606). Reported results are from a linear regression of change in 
FEV1/FVC on SNP (coded additively) controlling for age, gender, pack-years 
smoked, height, baseline spirometry, and principal components. 
Definition of abbreviations: CHR = chromosome; SNP = single nucleotide 












Supplementary Figure 4.4 
Change in FEV1 percent predicted by GOLD classification. GOLD 0 is defined as 
FEV1/FVC > 0.7. GOLD 1 is defined as FEV1/FVC < 0.7 and FEV1 ≥ 80% of 
normal. GOLD 2 is defined as FEV1/FVC < 0.7 and FEV1 50- 80% of normal. 
GOLD 3 is defined as FEV1/FVC < 0.7 and FEV1 30- 50% of normal. GOLD 3 is 
defined as FEV1/FVC < 0.7 and FEV1 <30% of normal. GOLD 0 and GOLD 4 












Supplementary Figure 4.5 
Change in FEV1/FVC by GOLD classification. GOLD 0 is defined as FEV1/FVC > 0.7. 
GOLD 1 is defined as FEV1/FVC < 0.7 and FEV1 ≥ 80% of normal. GOLD 2 is defined as 
FEV1/FVC < 0.7 and FEV1 50- 80% of normal. GOLD 3 is defined as FEV1/FVC < 0.7 
and FEV1 30- 50% of normal. GOLD 3 is defined as FEV1/FVC < 0.7 and FEV1 <30% of 

































Chapter 5. Summary of key finding and conclusions. 
Chronic obstructive pulmonary disease (COPD) is the 3rd leading cause of death 
worldwide, accounting for approximately 3 million deaths in 20101. Although cigarette 
smoking is the primary environmental risk factor, COPD susceptibility is related in part to 
genetic variation2–5. Most previous research has focused on identifying associations of 
common variants with cross-sectional lung function. We hypothesized: 1) rare functional 
variation also affects lung function; and 2) genetic variation (both common and rare) 
affects longitudinal changes in lung function. This dissertation addresses these two 
hypotheses with the following specific aims: 
1. To identify functional genetic variants associated with lung function in Non-
Hispanic White (NHW) and African American (AA) participants of the 
COPDgene study using exome array data. 
2. To identify genetic variants associated with longitudinal changes in lung 
function in Non-Hispanic White and African American participants of the 
COPDgene study using GWAS and exome array data. 
 
Summary of key findings 
Exome array analysis of lung function 
We aimed to identify rare coding variation associated with quantitative spirometric 
phenotypes through single variant and gene-based exome array analysis in the 
COPDgene study. We replicated previously known associations from genome-wide 
association studies (rs2070600 in AGER and rs16969968 in CHRNA5), illustrating the 
potential utility of studying the coding genome to clarify GWAS loci. In addition, we 
identified two novel associations in the ANK1 and ProSAPiP1 genes. Association signals 
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in these genes were largely driven by a single rare, nonsynonomous variant with a large 
effect (rs34664882 in ANK1 and rs140282982 in ProSAPiP1). Additional replication and 
functional validation of these variants is necessary, but together these results suggest 
searching the exome for additional loci influencing lung function loci may improve our 
understanding of genetic risk factors for COPD. 
Analysis of longitudinal changes in lung function 
We assessed the role of genetic risk factors in longitudinal changes in spirometric 
measures (FEV1 percent predicted and FEV1/FVC) using GWAS and exome array data 
from the COPDgene study. This preliminary genome-wide analysis yielded no 
statistically significant findings, suggesting no single variant can explain a large portion 
of the phenotypic variance of lung function changes over a 5-year period. The top SNP 
associated with change in FEV1 percent predicted analysis, rs17688693, is located in the 
nucleoporin 153 (NUP153), gene and the top associations in the change in FEV1/FVC 
analysis, rs12574104 and rs16937161, were located in the intergenic region between 
two pseudo genes (LOC100507205 and HNRNPKP3). Replication and functional 
validation of these associations is necessary. Additionally, we sought confirmatory 
evidence of association for genes previously associated with decline in lung function6–8. 
Our results support the involvement of one gene, nuclear factor 1A (NFIA), which 
showed suggestive evidence of association with change in FEV1 percent predicted in 
both the NHW and AA groups (p=0.0006 in NHWs and p=0.0009 in AAs).  
Although the heritability of lung function decline is established 9,10, genes controlling this 
phenotype remain largely unknown. To date, large GWAS analyses, including those 
presented in this dissertation, have failed to produce replicable results8. This negative 
result is likely due to: 1) imprecise measurement of smoking behaviors (especially failure 
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to account for changes in smoking behavior over time); and 2) differential lung function 
decline by disease severity (i.e. lung function decline may decelerate in those with more 
severe disease). However, despite these challenges, identifying risk factors for 
accelerated disease progression is key to identifying those at highest risk and 
subsequently improving clinical outcomes. Future large epidemiological studies are 
warranted.  
Strengths and limitations 
Strengths 
This dissertation has a few key strengths. The COPDgene study is a large, well-
characterized study that included both Non-Hispanic White and African American 
participants. Spirometric measurements were carefully collected, post-bronchodilation, 
using a standardized protocol. Unlike many population-based cohorts, COPDgene is 
unique in that many subjects have severe or very severe COPD (FEV1 percent predicted 
< 50%). 
Additionally, this is one of the first studies to assess the role of rare genetic variation in 
influencing quantitative measures of lung function and lung function decline. While 
traditional candidate gene and GWAS analyses can identify indirect associations 
between tagging SNPs and a quantitative phenotype, the exome array affords the 
opportunity to directly observe functional variation, potentially aiding to elucidate the 
mechanisms underlying risk of COPD. Additionally, we queried common and functional 
variants across the genome in a manner that it is unbiased with respect to previous 
knowledge of lung function etiology. Therefore, our analyses had the potential reveal 





This dissertation should be interpreted in light of its limitations. While we have detailed 
which smoking behaviors we analyzed, these common measures of exposure may not 
fully capture critical aspects of smoking, especially given these data are based on self-
report. Specifically, participants may not have reported changes in smoking behaviors 
over their lifetime, potentially resulting in residual confounding that could bias reported 
results. Moreover, available measures of smoking behaviors (pack-years smoked and 
current smoking status) may not completely capture the toxic effects of tobacco.  
Additionally, this dissertation used genotype data from Illumina’s HumanExome array 
(chapters 3 and 4) and Illumina’s OmniExpress GWAS array (chapter 4). Although these 
genotyping platforms cover common and coding variants relatively well11,12, they do not 
cover all genetic variation. Specifically, rare variants in non-coding regions and very rare 
variation (e.g. private mutations) are not covered. It is possible that loci affecting lung 
function will not be represented on the tested platforms, and therefore could not have 
been identified in this study. 
Lastly, our genome-wide analyses of lung function decline had limited sample size 
(n=1,394 NHWs and n=606 AAs), and therefore limited statistical power to detect 
genetic associations. Failure to identify statistically significant results likely reflects this 
limitation. As longitudinal follow-up continues in the COPDgene study, this additional 
data will greatly improve our ability to detect associations.  
Future directions 
Additional COPD-related phenotypes 
Spirometric phenotypes are reliable indicators of lung function and predict population 
mortality13. However, they do not fully describe the heterogeneous nature of COPD. 
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Specially, they do not differentiate between small airway disease and emphysema, the 
two main components of COPD pathogenesis. One unique advantage of the COPDgene 
study is that all participants underwent computed tomography (CT) imaging, allowing for 
more refined phenotyping to assess structural lung disease. Future analyses will focus 
on identifying genetic determinants of COPD-related phenotypes other than spirometry, 
including, percent emphysema, percent gas trapping, airway wall thickness and chronic 
bronchitis.  
Whole exome and whole genome sequencing 
In order to comprehensively study all genetic variation for its association with lung 
function, sequencing data is necessary. The COPDgene study is generating whole 
exome and whole genome sequencing on a subset of its 10,000 participants, and these 
data will allow for more complete evaluation of very rare and non-coding variation with 
COPD-related outcomes. 
Ongoing longitudinal follow-up 
The longitudinal analysis included in this dissertation represented approximately 20% of 
the COPDgene cohort expected to completed 5-year follow-up. The additional sample 
size afforded as more longitudinal data is collected will aid in the continued study of risk 
factors (both genetic and environmental) related to changes in lung function over time in 
this cohort of adults at high risk of COPD. 
Public health significance 
This study aims to elucidate genetic variants associated with lung function and 
longitudinal lung function decline. Reduced lung function defines COPD, a common 
disease with a high global burden1. This is one of the first studies to assess the role of 
rare genetic variants in disease pathogenesis, and we identified novel loci associated 
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with obstructive pulmonary disease. With replication, identification of associated variants 
can broaden our understanding of the biological pathways related to this disease. 
Ultimately, the goal of studying COPD genetics is to provide evidence for clinical practice 
and prevention. Improved understanding will aid in tailoring treatments to defined COPD 
subtypes, discovering novel therapeutic interventions and developing effective 
prevention strategies. This is especially timely given the large and growing burden of 
COPD1. 
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